Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer

被引：6

作者：

Motobayashi, Hideki ^{[1
]}

Kitahata, Yuji ^{[1
]}

Okada, Ken-ichi ^{[1
]}

Miyazawa, Motoki ^{[1
]}

Ueno, Masaki ^{[1
]}

Hayami, Shinya ^{[1
]}

Miyamoto, Atsushi ^{[1
]}

Shimizu, Atsushi ^{[1
]}

Sato, Masatoshi ^{[1
]}

Yoshimura, Tomohiro ^{[1
]}

Nakamura, Yuki ^{[1
]}

Takemoto, Norio ^{[1
]}

Nakai, Tomoki ^{[1
]}

Hyo, Takahiko ^{[1
]}

Matsumoto, Kyohei ^{[1
]}

Yamaue, Hiroki ^{[2
]}

Kawai, Manabu ^{[1
]}

机构：

[1] Wakayama Med Univ, Sch Med, Dept Surg 2, 811-1 Kimiidera, Wakayama 6418510, Japan

[2] Wakayama Med Univ, Dept Canc Immunol, Wakayama, Japan

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2024年 / 150卷 / 02期

关键词：

Advanced pancreatic cancer; Systemic chemotherapy; Therapeutic efficacy; Real-time biomarkers; Molecular response; LIQUID BIOPSIES; NAB-PACLITAXEL; GEMCITABINE; FOLFIRINOX; SURVIVAL; CHEMOTHERAPY; SURROGATE;

D O I：

10.1007/s00432-023-05594-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose We investigated the potential clinical utility of short-term serial KRAS-mutated circulating cell-free tumor DNA (ctDNA) assessment for predicting therapeutic response in patients undergoing first-line chemotherapy for advanced pancreatic cancer. Methods We collected 144 blood samples from 18 patients with locally advanced or metastatic cancer that were undergoing initial first-line chemotherapy of gemcitabine plus nab-paclitaxel (GEM plus nab-PTX). Analysis of KRAS-mutated ctDNA was quantified by digital droplet polymerase chain reaction (ddPCR) as mutant allele frequency (MAF). This study investigated pretreatment KRAS-mutated ctDNA status and ctDNA kinetics every few days (days 1, 3, 5 and 7) after initiation of chemotherapy and their potential as predictive indicators. Results Of the 18 enrolled patients, an increase in KRAS-mutated ctDNA MAF values from day 0-7 after initiation of chemotherapy was significantly associated with disease progression (P < 0.001). Meanwhile, positive pretreatment ctDNA status (MAF >= 0.02%) (P = 0.585) and carbohydrate antigen 19-9 (CA19-9) values above the median (P = 0.266) were not associated with disease progression. In univariate analysis, this short-term increase in ctDNA MAF values (day 0-7) was found to be associated with significantly shorter progression free survival (PFS) (hazard ration [HR], 24.234; range, (2.761-212.686); P = 0.0002). Conclusion This short-term ctDNA kinetics assessment may provide predictive information to reflect real-time therapeutic response and lead to effective refinement of regimen in patients with advanced pancreatic cancer undergoing systemic chemotherapy.

引用

页数：13

共 34 条

[1] High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients [J].

Allenson, K. ;

Castillo, J. ;

San Lucas, F. A. ;

Scelo, G. ;

Kim, D. U. ;

Bernard, V. ;

Davis, G. ;

Kumar, T. ;

Katz, M. ;

Overman, M. J. ;

Foretova, L. ;

Fabianova, E. ;

Holcatova, I. ;

Janout, V. ;

Meric-Bernstam, F. ;

Gascoyne, P. ;

Wistuba, I. ;

Varadhachary, G. ;

Brennan, P. ;

Hanash, S. ;

Li, D. ;

Maitra, A. ;

Alvarez, H. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :741-747

[2] Genomic analyses identify molecular subtypes of pancreatic cancer [J].

Bailey, Peter ;

Chang, David K. ;

Nones, Katia ;

Johns, Amber L. ;

Patch, Ann-Marie ;

Gingras, Marie-Claude ;

Miller, David K. ;

Christ, Angelika N. ;

Bruxner, Tim J. C. ;

Quinn, Michael C. ;

Nourse, Craig ;

Murtaugh, L. Charles ;

Harliwong, Ivon ;

Idrisoglu, Senel ;

Manning, Suzanne ;

Nourbakhsh, Ehsan ;

Wani, Shivangi ;

Fink, Lynn ;

Holmes, Oliver ;

Chin, Vencssa ;

Anderson, Matthew J. ;

Kazakoff, Stephen ;

Leonard, Conrad ;

Newell, Felicity ;

Waddell, Nick ;

Wood, Scott ;

Xu, Qinying ;

Wilson, Peter J. ;

Cloonan, Nicole ;

Kassahn, Karin S. ;

Taylor, Darrin ;

Quek, Kelly ;

Robertson, Alan ;

Pantano, Lorena ;

Mincarelli, Laura ;

Sanchez, Luis N. ;

Evers, Lisa ;

Wu, Jianmin ;

Pinese, Mark ;

Cowley, Mark J. ;

Jones, Marc D. ;

Colvin, Emily K. ;

Nagrial, Adnan M. ;

Humphrey, Emily S. ;

Chantrill, Lorraine A. ;

Mawson, Amanda ;

Humphris, Jeremy ;

Chou, Angela ;

Pajic, Marina ;

Scarlett, Christopher J. .

NATURE, 2016, 531 (7592) :47-+

[3] Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer [J].

Bernard, Vincent ;

Kim, Dong U. ;

San Lucas, F. Anthony ;

Castillo, Jonathan ;

Allenson, Kelvin ;

Mulu, Feven C. ;

Stephens, Bret M. ;

Huang, Jonathan ;

Semaan, Alexander ;

Guerrero, Paola A. ;

Kamyabi, Nabiollah ;

Zhao, Jun ;

Hurd, Mark W. ;

Koay, Eugene J. ;

Taniguchi, Cullen M. ;

Herman, Joseph M. ;

Javle, Milind ;

Wolff, Robert ;

Katz, Matthew ;

Varadhachary, Gauri ;

Maitra, Anirban ;

Alvarez, Hector A. .

GASTROENTEROLOGY, 2019, 156 (01) :108-+

[4] Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer [J].

Boeck, Stefan ;

Haas, Michael ;

Laubender, Ruediger P. ;

Kullmann, Frank ;

Klose, Christina ;

Bruns, Christiane J. ;

Wilkowski, Ralf ;

Stieber, Petra ;

Holdenrieder, Stefan ;

Buchner, Hannes ;

Mansmann, Ulrich ;

Heinemann, Volker .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :986-994

[5] Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer [J].

Buscail, Louis ;

Bournet, Barbara ;

Cordelier, Pierre .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) :153-168

[6] Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study [J].

Cabasag, Citadel J. ;

Arnold, Melina ;

Rutherford, Mark ;

Bardot, Aude ;

Ferlay, Jacques ;

Morgan, Eileen ;

Little, Alana ;

De, Prithwish ;

Dixon, Elijah ;

Woods, Ryan R. ;

Saint-Jacques, Nathalie ;

Evans, Sue ;

Engholm, Gerda ;

Elwood, Mark ;

Merrett, Neil ;

Ransom, David ;

O'Connell, Dianne L. ;

Bray, Freddie ;

Soerjomataram, Isabelle .

BRITISH JOURNAL OF CANCER, 2022, 126 (12) :1774-1782

[7] Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients [J].

Cheng, He ;

Liu, Chen ;

Jiang, Jiahao ;

Luo, Guopei ;

Lu, Yu ;

Jin, Kaizhou ;

Guo, Meng ;

Zhang, Zhenzhen ;

Xu, Jin ;

Liu, Liang ;

Ni, Quanxing ;

Yu, Xianjun .

INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (10) :2344-2350

[8] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

[9] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[10] Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer [J].

Earl, Julie ;

Garcia-Nieto, Sandra ;

Carlos Martinez-Avila, Jose ;

Montans, Jose ;

Sanjuanbenito, Alfonso ;

Rodriguez-Garrote, Mercedes ;

Lisa, Eduardo ;

Mendia, Elena ;

Lobo, Eduardo ;

Malats, Nria ;

Carrato, Alfredo ;

Guillen-Ponce, Carmen .

BMC CANCER, 2015, 15

← 1 2 3 4 →